Skip to main content

NuCana PLC (NCNA)

NASDAQ: NCNA · IEX Real-Time Price · USD
2.50
-0.01 (-0.40%)
After-hours:Oct 22, 2021 7:20 PM EDT
2.51
-0.06 (-2.33%)
At close: Oct 22, 4:00 PM
Market Cap131.45M
Revenue (ttm)n/a
Net Income (ttm)-54.49M
Shares Out52.16M
EPS (ttm)-1.14
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume451,833
Open2.56
Previous Close2.57
Day's Range2.50 - 2.59
52-Week Range1.88 - 7.83
Beta0.77
AnalystsStrong Buy
Price Target17.00 (+577.3%)
Est. Earnings DateNov 18, 2021

About NCNA

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian can...

IndustryBiotechnology
IPO DateSep 28, 2017
CEOHugh Griffith
Employees28
Stock ExchangeNASDAQ
Ticker SymbolNCNA
Full Company Profile

Financial Performance

Financial numbers in millions GBPFinancial Statements

Analyst Forecast

According to 8 analysts, the average rating for NuCana stock is "Strong Buy." The 12-month stock price forecast is 17.00, which is an increase of 577.29% from the latest price.

Price Target
$17.00
(577.29% upside)
Analyst Consensus: Strong Buy

News

NCNA Stock: The Big Cancer Drug News Sending NuCana Skyrocketing

NuCana (NCNA) stock is surging higher on Wednesday after the company revealed fast track designation from the FDA for Acelarin. The post NCNA Stock: The Big Cancer Drug News Sending NuCana Skyrocketing ...

3 weeks ago - InvestorPlace

Why Are NuCana Shares Moving Higher On Wednesday?

The FDA has granted Fast Track designation to NuCana plc's (NASDAQ: NCNA) Acelarin (NUC-1031) for the first-line treatment of patients with advanced biliary tract cancer. The Company recently announced ...

3 weeks ago - Benzinga

NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Tr...

EDINBURGH, United Kingdom, Sept. 29, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Acelarin (NUC-103...

3 weeks ago - GlobeNewsWire

NuCana Announces Four Poster Presentations at the ESMO Congress 2021

NUC-3373 Continues to Demonstrate Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer

1 month ago - GlobeNewsWire

NuCana Announces Enrollment of Required Number of Patients to Conduct First Interim Analysis in the Phase III Biliary...

Enrollment of 418 Evaluable Patients Expected to Enable First Interim Analysis in the First Half of 2022

1 month ago - GlobeNewsWire

7 Bargain Stocks to Buy Under $5 With the Right Catalysts

The risk in these inexpensive bargain stocks is offset by their upside for investors looking for a little more spice in their portfolio. The post 7 Bargain Stocks to Buy Under $5 With the Right Catalyst...

1 month ago - InvestorPlace

NuCana Reports Second Quarter 2021 Financial Results and Provides Business Update

EDINBURGH, United Kingdom, Aug. 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2021 and provided an update on its broad clinical...

2 months ago - GlobeNewsWire

7 Penny Stocks to Buy if You Want Potential Multibaggers

Here's a list of interesting penny stocks to buy that have lucrative prospects if you're willing to risk it for tremendous upside. The post 7 Penny Stocks to Buy if You Want Potential Multibaggers appea...

Other symbols:COECRNTRMTISTMH
2 months ago - InvestorPlace

NuCana Reports First Quarter 2021 Financial Results and Provides Business Update

Presented Encouraging Clinical Data at ASCO-GI and AACR

5 months ago - GlobeNewsWire

NuCana to Participate in the 7th Annual Truist Securities Life Sciences Summit

EDINBURGH, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one...

5 months ago - GlobeNewsWire

NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2...

6 months ago - GlobeNewsWire

NuCana Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update

Presented Encouraging Clinical Data for NUC-3373 and NUC-7738

7 months ago - GlobeNewsWire

3 Biotech Stocks That Jumped Last Week

Find out what led to the biotech industry's biggest gains.

Other symbols:ALDXLXRX
9 months ago - The Motley Fool

NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal C...

Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy

9 months ago - GlobeNewsWire

NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session

NuCana (NCNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

NuCana Appoints Andrew Kay as Board Chairman

Pharmaceutical Executive Brings a Wealth of Experience to NuCana's Board of Directors

10 months ago - GlobeNewsWire

Final Data from the Phase Ib Study of Acelarin plus Cisplatin in Patients with Advanced Biliary Tract Cancer Publishe...

Acelarin plus Cisplatin's High Objective Response Rate and Favorable Safety Profile Confirmed

10 months ago - GlobeNewsWire

NuCana Reports Third Quarter 2020 Financial Results and Provides Business Update

Completed Successful $ 8 0 million Public Offering

11 months ago - GlobeNewsWire

NuCana to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

EDINBURGH, United Kingdom, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present a...

11 months ago - GlobeNewsWire

NuCana to Present at the Jefferies Virtual London Healthcare Conference

EDINBURGH, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present a...

11 months ago - GlobeNewsWire

Why NuCana (NCNA) Might Surprise This Earnings Season

NuCana (NCNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

11 months ago - Zacks Investment Research

NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar

Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public Offering Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public Offering

1 year ago - GlobeNewsWire

NuCana (NCNA) Surges: Stock Moves 6.3% Higher

NuCana (NCNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

NuCana Presents Three Posters at the ESMO Virtual Congress 2020

Encouraging Efficacy Signals Observed in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer in the Phase Ib Study of NUC-3373 (NuTide:302)

1 year ago - GlobeNewsWire

NuCana Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option t...

EDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, ann...

1 year ago - GlobeNewsWire